Advertisement


Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

2023 ASCO Annual Meeting

Advertisement

Sebastian Stintzing, MD, of the Charité Universitätsmedizin Berlin, discusses results from the phase III FIRE-4 study, which showed that liquid biopsy is clinically relevant in verifying mutational status in patients with metastatic colorectal cancer and is efficacious in first-line treatment of FOLFIRI and cetuximab for patients with RAS wild-type disease (Abstract 3507).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The purpose of the FIRE-4 study was to test whether a switch maintenance from an anti-EGFR containing regimen first-line to bevacizumab plus [inaudible 00:00:19] would prevent upcoming RAS mutations as secondary resistant factors and therefore prolong progression-free survival over the median time that is reached with the standard treatment of FOLFIRI plus cetuximab. Therefore, we randomized 672 patients in either FOLFIRI plus cetuximab until progression or intolerable toxicity versus FOLFIRI cetuximab up to eight and 12 cycles, and then switch maintenance towards [inaudible 00:00:52] and bevacizumab. Primary endpoint of the first line treatment was PFS and we have published this in last year, we did not reach a PFS. PFS of both arms was comparable. At this ASCO, we present the data of the liquid biopsy translational program. We took liquid biopsies at the beginning, at baseline, at the 6 to 12 cycles within treatment. And then at the end of the treatment, at progression. What was quite unexpected, this was a RAS wide type population by tissue-based testing within the liquid biopsy, we were able to find 13% of patients having a RAS mutation at baseline. And the outcome of those patients were as expected for RAS mutant patients. At PFS of roundabout nine months and overall survival of 22 months, whereas the double Y type population, the RAS and BUFY type population exceeded the PFS with 11.5 months and then overall exceeding in median 33 months. We also had the on treatment measurement of liquid biopsy and was quite interesting. It took in median 48 weeks until the RAS mutation came up in those patient treated continuously with anti-EGFR treatment. Almost after one year of treatment, there were upcoming RAs mutations and we found those in round about 19%. One out of five patients got to this RAS mutation. It did not impact overall survival. What are our conclusions here? First of all, baseline liquid biopsy is important to find the right patient population and to sort out those patient who may have a RAS wide type tumor by tissue-based analysis, but a RAS mutant tumor by liquid biopsy because those patients do not derive benefit from anti-EGFR treatment. At baseline it's important, it's meaningful. During treatment, we think there's no meaning for the RAS testing by liquid biopsy because those patients who actually got a RAS mutation during treatment have a very long treatment time, are on treatment for almost a year. And it has no impact on overall survival. What would be the next steps? In my opinion, we should do a liquid biopsy in our clinical practice before starting anti-EGFR treatments or at baseline to cover tumor heterogeneity and to cover the real RAS mutational status of our patients that we want to treat. B, I think it'll be important to find a threshold during treatment where we can apply treatment holidays. Where's the threshold? How far can we actually treat the patients? How far can we shrink down the tumor volume until it is safe to say, okay, now we can do a treatment holiday, just to give the patient a break and from a patient perspective to have a better quality of life during this treatment course.

Related Videos

Lung Cancer

Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib

Rami Manochakian, MD, of Mayo Clinic Florida, offers his perspective on the new phase III findings on osimertinib, a third-generation, central nervous system EGFR tyrosine kinase inhibitor, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA non–small cell lung cancer (NSCLC) after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3).

Ajay K. Nooka, MBBS, Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Data for Elranatamab

Ajay K. Nooka, MBBS, of Winship Cancer Center of Emory University, discusses findings from a pooled analysis of MagnetisMM studies. The data showed that, in patients with relapsed or refractory multiple myeloma who have not yet been treated with B-cell maturation antigen–directed therapies, elranatamab was efficacious and well tolerated.

Lymphoma

Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options

Manali K. Kamdar, MD, of University of Colorado Hospital, discusses the treatment landscape for the 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) whose disease will relapse. Patients who experience relapse within 1 year of chemoimmunotherapy have poor outcomes with autotransplantation, but chimeric antigen receptor T-cell therapy has shown efficacy and manageable toxicity.

Lymphoma

Reid Merryman, MD, on High-Risk Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Reid Merryman, MD, of Dana-Farber Cancer Institute, discusses his findings on the regimen of epcoritamab plus rituximab and lenalidomide for patients with high-risk follicular lymphoma. Regardless of whether their disease progressed within 24 months of first-line chemoimmunotherapy, this regimen showed antitumor activity and a manageable safety profile in patients with relapsed or refractory disease. Epcoritamab, a subcutaneous T-cell–engaging bispecific antibody, may abrogate the negative effects of high-risk features (Abstract 7506).

Global Cancer Care
Leukemia

Paula Aristizabal, MD, MAS, on Surviving Childhood Leukemia Near the Border of the United States and Mexico

Paula Aristizabal, MD, MAS, of the University of California, San Diego, and Rady Children’s Hospital, talks about using a health systems strengthening approach to improve leukemia care and survival in a public Mexican hospital in the region of the border between the United States and Mexico. The demonstrated increase in overall survival across a decade after implementation of the program seems to validate the use of such models, not only to improve clinical outcomes, but also to build sustainable hospital capacity, financially and organizationally (Abstract 1502).

Advertisement

Advertisement




Advertisement